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Identity 
Other names: C17orf37, C35, ORB3, RDX12, XTP4 




MIEN1 DNA contains 4 coding exons over 1,63 kb on 
the minus strand between ERBB2 and GRB7 on human 
chromosome 17q12. It is also neighbouring 
mRNA4728. 
Transcription 
Transcript (NC_000017.100) length: 1006 bps. 
Transcription was reported in a variety of cell lines and 






MIEN1 is a small (12 kDa) membrane bound protein 
found in a variety of human tumours (Evans et al., 
2006).  
Its main function is to induce cell invasion and it may 
be involved in metastasis (Dasgupta et al., 2011; 
Dasgupta and Vishwanatha, 2007; Katz et al., 2010). 
Expression 
MIEN1 is almost exclusively expressed in human 
tumours, with the notable exception of Leydig cells in 
testes (Evans et al., 2006). 
Localisation 
MIEN1 protein is membrane bound and its stability 
depends on its localization (our unpublished 
observations). MIEN1 contains a CVIL amino acid 
sequence in the C-terminal, which fits the prenylation 
motif CaaX (Evans et al., 2006). Based on several 
physical properties, such as size, flexibility, membrane 
buried preference, and presence of leucine as the X 
residue, MIEN1 is predicted to be geranylgeranylated 
in vivo by GGTI enzyme, resulting in the addition of 
20-carbon isoprenoid moiety. 
Function 
The MIEN1 sequence EATYLELASAVKEQYPGIEI 
conforms to a prototypical immuno-receptor tyrosine-
based activation motif (ITAM). ITAMs, such as this of 
C35 rely on Syk protein kinase for their signaling 
capacities (Katz et al., 2010). The most commonly 
reported consequence of MIEN1 over-expression is the 
induction of cell motility and invasion (Dasgupta et al., 
2011; Katz et al., 2010). High levels of MIEN1 
expression lead to epithelial to mesenchymal transitio  
in breast cell lines (Katz et al., 2011a). However, 
intermediate levels lead to a cancer phenomenon rarely 
observed in experimental models, collective invasion 
(Katz et al., 2011b). 
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With permission by Hsu et al. (Hsu et al., 2012). 
 
Homology 
MIEN1 is very highly conserved among six higher 
eukaryotic species (identities >77%) but does not seem 
to have orthologues in microbial organisms (Evans et 
al., 2006).  
MIEN1 contains an ITAM motif which is prevalent in 
immune receptors as well as oncogenic viruses. 
Mutations 
Note 
A single SNP, rs3809717, was described with no 
bearing on breast cancer risk (attributed originally to 




Several carcinomas (breast, ovarian, and gastro-
intestinal cancers) show high expression of the ERBB2 
amplicon containing the MIEN1 gene. 
Breast cancer 
Disease 
Over-expression of ERBB2 amplicon is seen in ~20% 
of breast cancers and it confers worse biological 
behavior and clinical aggressiveness in breast cancer.  
Breast cancers can have up to 25 to 50 copies of the 
ERBB2 amplicon.  
MIEN1 is one of the core ERBB2 genes which are 
always over-expressed with ERBB2/HER2 
(Kauraniemi et al., 2003). 
 
Prognosis 
The prognosis of MIEN1 over-expressing breast cancer 
is indistinguishable from those of ERBB2 over-
expressing breast cancers, due to the common 
amplification (Katz et al., 2010). 
Prostate cancer 
Disease 
MIEN1 is highly overexpressed in prostate cancer, 
where it modulates the Akt activity as a membrane 
bound adapter protein (Dasgupta et al., 2009). MIEN1 
is post-translationaly modified by addition of prenyl 
groups that translocates the protein to the inner face of 
the plasma membrane.  
Ectopic expression of MIEN1 activates Akt and 
cascades downstream signaling through NF-κB 
pathway upregulating expression of several migratory 
and invasive genes (Dasgupta et al., 2011).  
MIEN1 may act as a scaffolding protein blocking 
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